May 12, 2010

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
TOHO HOLDINGS CO., LTD.
(Tokyo Stock Exchange Securities Code: 8129)
Norio Hamada, President and CEO
Contact:
Katsuya Kato
Corporate Officer and General Manager of
Corporate Communications Office
(TEL: 03-5259－9520)

Results of Operations for Fiscal Year Ended March 2010

Consolidated sales for the fiscal year ended March 2010 increased by 163,219 million yen (up 19.5%) from the previous year to 1,002,122 million yen, surpassing 1 trillion yen for the first time since the Company's foundation in 1948, due primarily to ASUCOME CO., LTD. (which became TOHO HOLDINGS' consolidated sub-subsidiary on February 1, 2010) and OMWELL Inc. (which became TOHO HOLDINGS' consolidated subsidiary on October 1, 2009 and then merged with SANUS Inc. on January 1, 2010 to form the current SAYWELL Inc.) having sequentially launched cooperative purchasing (products are supplied by TOHO HOLDINGS' subsidiary, TOHO PHARMACEUTICAL CO., LTD.) since April. Other contributors to the strong sales include growth assisted by the appreciation by the customers of proposal-based marketing and sales activities based on the pillar of the Company's unique customer support system and the growth of sales of pharmaceuticals for lifestyle-related diseases and new pharmaceuticals, as well as increasing demand for pharmaceuticals related to the outbreak of a new sub-type of influenza.

In terms of profits, operating income, ordinary income and net income all significantly surpassed the corresponding results of the full fiscal 2009 supported by efforts to minimize product price declines, a solid expansion of the dispensing pharmacy business, curbed growth of SGA expenses, and although expected to have a detrimental impact on the Company's earnings at the end of the fiscal year, the ratio of manufacturer invoice price affected by the introduction of the new drug pricing system having remained more or less in line with the Company's prediction. As a consequence, the gross profit rate improved by 0.7% from the full fiscal 2009 to 8.1%. Since the SGA expenses rate decreased by 0.1% from the preceding year to 7.0% due to slowed growth of SGA expenses, the operating income to net sales ratio improved by 0.7% from the previous year to 1.1% with operating income increasing by 7,918 million yen or 262.0%, year on year. Meanwhile, ordinary income surged by 7,608 million yen from the same period of the previous year, with the ordinary income to net sales ratio improving by 0.6% to 1.4%. Net income also soared by 10,734 million yen from the previous year.

1. Financial Results for Fiscal 2010. (Consolidated)

(1) Comparison with the same period in the previous fiscal year

Unit: million yen, %

Consolidated	Net Sales	Operating Income	Ordinary Income	Net Income
Fiscal 2010	1,002,122	10,939	14,133	8,263
Fiscal 2009	838,903	3,021	6,525	-2,471
YoY Change	163,219	7,918	7,608	10,734
YoY Change Ratio	119.5	262.0	116.6	—

(2) Comparison with the forecast for full fiscal 2010

Unit: million yen, %

Consolidated	Net Sales	Operating Income	Ordinary Income	Net Income
Fiscal 2010	1,002,122	10,939	14,133	8,263
Forecast for the Fiscal 2010 (Released on February 4)	980,000	7,500	10,500	5,500
Percentage against the Full-year Earnings Forecasts	102.3	145.9	134.6	150.2

(3) Gross profit rates, SGA expenses rate, Operating income ratio and Ordinary income ratio (Year-on-year change)

Unit : %

Consolidated	Gross profit to net sales	SG&A expenses to net sales	Operating income to net sales	Ordinary income to net Sales
Fiscal 2010	8.1	7.0	1.1	1.4
Fiscal 2009	7.4	7.1	0.4	0.8
YoY Change Ratio	0.7	-0.1	0.7	0.6

2. Forecast for fiscal 2011 (Full-year)

Unit: million yen, %

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share
Fiscal 2011	1,060,000	12,000	14,700	8,300	※111.49
Fiscal 2010	1,002,122	10,939	14,133	8,263	125.69
Increase/Decrease	57,878	1,061	567	37	-14.20
Increase/Decrease Ratio	5.8	9.7	4.0	0.4	-11.3

* Net income per share

The calculation of net income per share is based on the average number of shares during the respective fiscal year. Since the average number of shares during the current fiscal year is expected to increase from the previous year as a result of the rise in the number of shares due to the stock swap implemented in the previous year, net income per share for fiscal 2011 is likely to decrease. (See "Earnings per share information" provided by the Summary of Consolidated Financial Results, p.77)

Although it is difficult to estimate the expected impact on the pharmaceutical wholesaling business of the new drug-pricing system including the introduction of a new scheme aiming to encourage the marketing of new innovative drugs and the resolution for off-label drug, the Company will endeavor to secure adequate profit through sales growth propelled by an increasing number of consolidated companies along with thorough price management. With regard to the dispensing pharmacy business, in addition to larger sales likely to be generated from an increasing number of consolidated companies, existing consolidated companies aim to continue boosting their management efficiency and implementing increasingly value-added operations.